Viropharma (VPHM) Shares Sink Amid Cinryze Data; Stifel Nicolaus Weighs In
Tweet Send to a FriendGet Alerts VPHM Hot Sheet
Price: $25.88 +1.01%
Rating Summary:
11 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
11 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade VPHM Now!
Shares of Viropharma (Nasdaq: VPHM) have tumbled nearly 7 percent Tuesday following the release of data on the company's subcutaneous Cinryze(R) with recombinant human hyaluronidase. The stock last traded at $30.50.
Stifel Nicolaus' Stephen Willey said in an earlier note Viropharma will likely need to show more dose-ranging data on the product's effectiveness. While the analyst noted 2,000-unit sub-Q data validates utilization of rHuPH20 usage with Cinryze, he warned logistical issues may pop up related to manufacturing capacity and cost before a twice-per-week dosing could be a feasible option. Willey also suggested the data confirms an unformulated sub-Q1 C1 inhibitor would not be a viable treatment option.
Despite the cautious comments, Stifel Nicolaus and Willey maintain a Buy rating and $42 price target on shares of Viropharma.
Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Viropharma.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Stifel Nicolaus' Stephen Willey said in an earlier note Viropharma will likely need to show more dose-ranging data on the product's effectiveness. While the analyst noted 2,000-unit sub-Q data validates utilization of rHuPH20 usage with Cinryze, he warned logistical issues may pop up related to manufacturing capacity and cost before a twice-per-week dosing could be a feasible option. Willey also suggested the data confirms an unformulated sub-Q1 C1 inhibitor would not be a viable treatment option.
Despite the cautious comments, Stifel Nicolaus and Willey maintain a Buy rating and $42 price target on shares of Viropharma.
Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Viropharma.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
Create E-mail Alert Related Categories
Analyst Comments, Corporate NewsRelated Entities
Stifel Nicolaus
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
